Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1

Fengyi Feng,Qing Li,Changquan Ling,Yang Zhang,Fengzhan Qin,Huaqing Wang,Wenxia Huang,Shunchang Jiao,Qiang Chen,Mingzhong Li,Zhu Yz,Meizhen Zhou,Jun Ren,Yetao Gao,Jingpo Zhao,Rongsheng Zheng,Wenhua Zhao,Zhiqiang Meng,Fang Li,Qizhong Zhang,Dongli Zhao,Liyan Xu,Yongqiang Zhang,Yanjun Zhang,Zhenjiu Wang,Shuanqi Liu,Ming C. Liau

Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1

2005

Objective The objective of this study was to explore the effect of CDA-2, a selective inhibitor of abnormal methylation enzymes in cancer cells, on the therapeutic efficacy of cytotoxic chemotherapy.

Keywords:

Breast cancer
Traditional medicine
Cancer cell
Clinical trial
Cancer
Cytotoxic T cell
Cancer research
Lung cancer
Chemotherapy
Differentiation therapy
Medicine
Phases of clinical research
Pathology
Methylation
Cellular differentiation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations